account_id none on file
legal_name ArriVent BioPharma, Inc.
ticker AVBP
cik 1868279
domain arrivent.com
linkedin_company_url https://www.linkedin.com/company/arrivent
entry_point_account_id none on file
name ArriVent BioPharma Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 3 executives 0 family 0
why_nownone on file
callsnone on file
filings
The increase of $14.6 million was primarily due to a $9.8 million increase in costs related to early-stage programs, $3.4 million increase in personnel-related costs due to increased headcount, and a $1.5 million increase in total costs related to our lead product candidate, firmonertinib.
filing / Aug 12, 2026 / receipt
The increase of $4.4 million was due primarily to increases in personnel-related costs, including increases in headcount, and consultant costs to support the growth in the overall business.
filing / Aug 12, 2026 / receipt
The decrease of $23.7 million was primarily due to a $28.6 million decrease in costs related to early-stage programs, offset by a $4.2 million increase in personnel-related costs due to increased headcount, and a $0.8 million increase in costs related to our lead product candidate, firmonertinib.
filing / May 11, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-09 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug arrivent-biopharma-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$